01
Cash & equivalents increased 35.8%
Cash & equivalents changed +35.8% from the comparable as-filed period.
$101.8M→$138.3MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTMineralys Therapeutics, Inc.'s latest supported as-filed period reports interest income of $5.0M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +35.8% from the comparable as-filed period.
Net income changed -457.1% from the comparable as-filed period.
Operating income changed -426.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
MLYS · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001916048-26-000012SEC ↗4Aug 12, 2026Period Aug 10, 20260001933414-26-000120SEC ↗4Aug 12, 2026Period Aug 10, 20260001933414-26-000118SEC ↗10-QAug 11, 2026Period Jun 30, 20260001933414-26-000114SEC ↗8-KAug 11, 2026Period Aug 5, 20260001933414-26-000112SEC ↗4Jul 23, 2026Period Jul 21, 20260001916048-26-000009SEC ↗4Jul 20, 2026Period Jul 17, 20260001672659-26-000036SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 21, 2026Filed Aug 25, 2026 | Warren EricChief Commercial Officer | Option ExerciseDirect | 7,437 | $13 | $98,466 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Warren EricChief Commercial Officer | Open Market SaleDirect | 7,437 | $26 | $193,189 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Warren EricChief Commercial Officer | Option ExerciseDirect | 7,437 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +478.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Stock-based compensation changed +61.5% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001933414-26-000100